GenMark

The firm anticipates that Q2 2020 revenues associated with its ePlex tests would increase by about 195 percent compared to Q2 2019.

Of the 28 companies in the index, 21 firms saw their stock prices increase throughout the first half of the year, while seven firms' share prices decreased.

Of the 28 companies in the index, 18 firms saw their stock prices increase, while 10 firms' share prices decreased. 

News items for the in vitro diagnostics industry for the week of June 15, 2020.

Of the 28 companies in the index, 21 firms saw their stock prices increase, while seven firms' share price decreased. 

GenMark said it intends to use the proceeds for general corporate purposes that may include an expansion of its menu and increasing its manufacturing capacity.

The company's revenue growth was driven by increasing sales of its ePlex molecular diagnostics analyzer, which now has a SARS-CoV-2 test.

Of the 28 companies in the index, 27 firms saw their stock prices increase, while one firm's share price decreased slightly.

Approximately 80 percent of gross product placements in the quarter were associated with interest in COVID-19 testing, the firm said

Of the 28 companies in the 360 Index, six companies' share prices increased while the share values of 22 declined month over month.